

Rec'd PTO 27 SEP 2005

Atty. Dkt. No. 059314-0801  
(previously 039386-2252)

#4

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Vicki ELLIOTT  
Title: IMMUNE RESPONSE  
ASSOCIATED PROTEINS  
Appl. No.: 10/525,743  
Filing Date: 09/26/2005  
Examiner: Unassigned  
Art Unit: Unassigned

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

**RELEVANCE OF EACH DOCUMENT**

All of the documents are in English.

Applicant respectfully requests that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date Sept 27, 2005

By Michele M. Simkin

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 672-5538  
Facsimile: (202) 672-5399

Michele M. Simkin  
Attorney for Applicant  
Registration No. 34,717

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number		10/525,743
				Filing Date		09/26/2005
				First Named Inventor		Vicki S. Elliott
				Group Art Unit		Unassigned
				Examiner Name		Unassigned
Sheet	1	of	18	Attorney Docket Number		059314-0701 (previously 039386-2252)

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	A1	6,372,724		Pelleg, <i>et al.</i>	April 16, 2002	
	A2	6,057,101		Nandabalan, <i>et al.</i>	May 2, 2000	
	A3	6,022,691		Bruice, <i>et al.</i>	February 8, 2000	
	A4	5,997,848		Patton, <i>et al.</i>	December 7, 1999	
	A5	5,932,435		Atkins, <i>et al.</i>	August 3, 1999	
	A6	5,914,236		Monsma, Jr., <i>et al.</i>	June 22, 1999	
	A7	5,910,434		Rigg, <i>et al.</i>	June 8, 1999	
	A8	5,840,484		Seilhamer, <i>et al.</i>	November 24, 1998	
	A9	5,837,458		Minshull, <i>et al.</i>	November 17, 1998	
	A10	5,807,522		Brown, <i>et al.</i>	September 15, 1998	
	A11	5,804,413		DeLuca	September 8, 1998	
	A12	5,767,337		Roses, <i>et al.</i>	June 16, 1998	
	A13	5,707,618		Armentano, <i>et al.</i>	January 13, 1998	
	A14	5,686,242		Bruice, <i>et al.</i>	November 11, 1997	
	A15	5,605,662		Heller, <i>et al.</i>	February 25, 1997	
	A16	5,474,796		Brennan	December 12, 1995	
	A17	5,270,163		Gold, <i>et al.</i>	December 14, 1993	
	A18	5,175,383		Leder, <i>et al.</i>	December 29, 1992	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	B1		WO 95/35505		The Board of Trustees of the Leland Stanford Junior University	December 28, 1995		

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/525,743
				Filing Date	09/26/2005
				First Named Inventor	Vicki S. Elliott
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	2	of	18	Attorney Docket Number	059314-0701 (previously 039386-2252)

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)		
	B2		WO 95/25116		California Institute of Technology	September 21, 1995
	B3		WO 84/03564		Commonwealth Serum Laboratories Commission	September 13, 1984

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C1	Abbas, A.K. <i>et al.</i> , "Role of the $\alpha\beta$ Receptor in Recognition of MHC-Associated Antigen," (1991) <u>Cellular and Molecular Immunology</u> , W.B. Saunders Company, Philadelphia, PA, pp.142-145	
	C2	Adam, M.A. and A.D. Miller, "Identification of a signal in a murine retrovirus that is sufficient for packaging of nonretroviral RNA into virions," (1988) <u>J. Virol.</u> 62:3802-3806	
	C3	Adams, M. <i>et al.</i> , "Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation," (1997) <u>J. Clin. Invest.</u> 100:3149-3153	
	C4	Altschul, S.F. <i>et al.</i> , "Basic local alignment search tool," (1990) <u>J. Mol. Biol.</u> 215:403-410	
	C5	Anderson, N.L. and J. Seilhamer, "A Comparison of Selected mRNA and Protein Abundances in Human Liver," (1997) <u>Electrophoresis</u> 18:533-537	
	C6	Antinozzi, P.A. <i>et al.</i> , "Metabolic engineering with recombinant adenoviruses," (1999) <u>Annu. Rev. Nutr.</u> 19:511-544	
	C7	Armentano, D. <i>et al.</i> , "Effect of internal viral sequences on the utility of retroviral vectors," (1987) <u>J. Virol.</u> 61:1647-1650	
	C8	Arndt, G.M. <i>et al.</i> , "A rapid genetic screening system for identifying gene-specific suppression constructs for use in human cells," (2000) <u>Nucleic Acids Res.</u> 28:E15	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/525,743
				Filing Date	09/26/2005
				First Named Inventor	Vicki S. Elliott
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	3	of	18	Attorney Docket Number	059314-0701 (previously 039386-2252)

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	C9	Ashkenazi, A. and V.M. Divit, "Apoptosis control by death and decoy receptors," (1999) <u>Curr. Opin. Cell Biol.</u> 11:255-260		
	C10	Auwerx, J., "PPAR $\gamma$ , The Ultimate Thrifty Gene," (1999) <u>Diabetologia</u> 42:1033-1049		
	C11	Baltimore, D., "Intracellular Immunization," (1988) <u>Nature</u> 335:395-396		
	C12	Barroso, I. <i>et al.</i> , "Dominant negative mutations in human PPAR $\gamma$ associated with severe insulin resistance, diabetes mellitus and hypertension," (1999) <u>Nature</u> 402:880-883		
	C13	Bauer, G. <i>et al.</i> , "Inhibition of Human Immunodeficiency Virus-1 (HIV-1) Replication After Transduction of Granulocyte Colony-Stimulating Factor-Mobilized D34 <sup>+</sup> Cells From HIV-1-Infected Donors Using Retroviral Vectors Containing Anti-HIV-1 Genes," (1997) <u>Blood</u> 89:2259-2267		
	C14	Becker, B.F. <i>et al.</i> , "Endothelial Function and Hemostasis," (2000) <u>Z. Kardiol.</u> 89:160-167		
	C15	Bender, M.A. <i>et al.</i> , "Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region," (1987) <u>J. Virol.</u> 61:1639-1646		
	C16	Bitter, G.A. <i>et al.</i> , "Expression and Secretion Vectors for Yeast," (1987) <u>Methods Enzymol.</u> 153:516-544		
	C17	Blaese, R.M. <i>et al.</i> , "T Lymphocyte-Directed Gene Therapy for ADA <sup>-</sup> SCID: Initial Trial Results After 4 Years," (1995) <u>Science</u> 270:475-480		
	C18	Blind, M. <i>et al.</i> , "Cytoplasmic RNA modulators of an inside-out signal-transduction cascade," (1999) <u>Proc. Natl. Acad. Sci. USA</u> 96:3606-3610		
	C19	Boado, R.J. <i>et al.</i> , "Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS," (1998) <u>J. Pharm. Sci.</u> 87:1308-1315		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Application Number</b>	10/525,743
				<b>Filing Date</b>	09/26/2005
				<b>First Named Inventor</b>	Vicki S. Elliott
				<b>Group Art Unit</b>	Unassigned
				<b>Examiner Name</b>	Unassigned
(use as many sheets as necessary)				<b>Attorney Docket Number</b>	059314-0701 (previously 039386-2252)
Sheet	4	of	18		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	C20	Bolton, A.E. and W.M. Hunter, "The Labelling of Proteins to High Specific Radioactivities by Conjugation to a <sup>125</sup> I-Containing Acylating Agent," (1973) <u>Biochem. J.</u> 133:529-539		
	C21	Bonyhadi, M.L., "RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication," (1997) <u>J. Virol.</u> 71:4707-4716		
	C22	Bordignon, C. <i>et al.</i> , "Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA Immunodeficient Patients," (1995) <u>Science</u> 270:470-475		
	C23	Boulay, J.-L. and H. Récipon, "Expression Vectors and Delivery Systems," (1998) <u>Curr. Opin. Biotechnol.</u> 9:445-450		
	C24	Bowie, A.G. and L.A. O'Neill, "Oxidative Stress and Nuclear Factor-κB Activation," (2000) <u>Biochem. Pharmacol.</u> 59:13-23		
	C25	Brody, E.N. and L. Gold, "Aptamers as Therapeutic and Diagnosis Agents," (2000) <u>J. Biotechnol.</u> 74:5-13		
	C26	Broglie, R. <i>et al.</i> , "Light-Regulated Expression of a Pea Ribulose-1,5-Bisphosphate Carboxylase Small Subunit Gene in Transformed Plant Cells," (1984) <u>Science</u> 224:838-843		
	C27	Brummelkamp, T.R. <i>et al.</i> , "A System for Stable Expression of Short Interfering RNAs in Mammalian Cells," (2002) <u>Science</u> 296:550-55		
	C28	Buller, R.M. <i>et al.</i> , "Decreased Virulence of Recombinant Vaccinia Virus Expression Vectors Is Associated With a Thymidine Kinase-Negative Phenotype," (1985) <u>Nature</u> 317:813-815		
	C29	Burge, C. and S. Karlin, "Finding the Genes in Genomic DNA," (1997) <u>J. Mol. Biol.</u> 268:78-94		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Application Number</b>	10/525,743
				<b>Filing Date</b>	09/26/2005
				<b>First Named Inventor</b>	Vicki S. Elliott
				<b>Group Art Unit</b>	Unassigned
				<b>Examiner Name</b>	Unassigned
(use as many sheets as necessary)				<b>Attorney Docket Number</b>	059314-0701 (previously 039386-2252)
Sheet	5	of	18		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C30	Burge, C. and S. Karlin, "Prediction of Complete Gene Structures in Human Genomic DNA," (1998) <u>Curr. Opin. Struct. Biol.</u> 8:346-354	
	C31	Burton, D.R., "A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals," (1991) <u>Proc. Natl. Acad. Sci. USA</u> 88:10134-10137	
	C32	Capecchi, M.R., "Altering the Genome by Homologous Recombination," (1989) <u>Science</u> 244:1288-1292	
	C33	Caruthers, M.H. <i>et al.</i> , "New chemical methods for synthesizing polynucleotides," (1980) <u>Nucleic Acids Symp. Ser.</u> 7:215-223	
	C34	Cavazzana-Calvo, M. <i>et al.</i> , "Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease," (2000) <u>Science</u> 288:669-672	
	C35	Chang, C.-C. <i>et al.</i> , "Evolution of a Cytokine Using DNA Family Shuffling," (1999) <u>Nat. Biotechnol.</u> 17:793-797	
	C36	Chen, L. <i>et al.</i> , "Overexpression of matrix Gla protein mRNA in malignant human breast cells: isolation by differential cDNA hybridization," (1990) <u>Oncogene</u> 5:1391-1395	
	C37	Chicz, R.M. and F.Z. Regnier, "High-Performance Liquid Chromatography: Effective Protein Purification by Various Chromatographic Modes," (1990) <u>Methods Enzymol.</u> 182:392-421	
	C38	Christians, F.C. <i>et al.</i> , "Directed Evolution of Thymidine Kinase for AZT Phosphorylation Using DNA Family Shuffling," (1999) <u>Nat. Biotechnol.</u> 17:259-264	
	C39	Clarke, M.L. <i>et al.</i> , "Comparative Analysis of Artificial Antisense RNA Regulation in Fission Yeast and Human Cells," (2000) <u>Biochem. Biophys. Res. Commun.</u> 268:8-13	
	C40	Colbere-Garapin, F. <i>et al.</i> , "A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells," (1981) <u>J. Mol. Biol.</u> 150:1-14	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Application Number</b>	10/525,743
				<b>Filing Date</b>	09/26/2005
				<b>First Named Inventor</b>	Vicki S. Elliott
				<b>Group Art Unit</b>	Unassigned
				<b>Examiner Name</b>	Unassigned
(use as many sheets as necessary)				<b>Attorney Docket Number</b>	059314-0701 (previously 039386-2252)
Sheet	6	of	18		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	C41	Cole, S.P. <i>et al.</i> , "Human monoclonal antibodies," (1984) <u>Mol. Cell Biol.</u> 62:109-120		
	C42	Coruzzi, G. <i>et al.</i> , "Tissue-Specific and Light-Regulated Expression of a Pea Nuclear Gene Encoding the Small Subunit of rebulose-1,5-Bisphosphate Carboxylase," (1984) <u>EMBO J.</u> 3:1671-1680		
	C43	Cote, R.J. <i>et al.</i> , "Generation of human monoclonal antibodies reactive with cellular antig," (1983) <u>Proc. Natl. Acad. Sci. USA</u> 80:2026-2030		
	C44	Cramer, A. <i>et al.</i> , "Improved Green Fluorescent Protein by Molecular Evolution Using DNA Shuffling," (1996) <u>Nat. Biotechnol.</u> 14:315-319		
	C45	Crystal, R.G. <i>et al.</i> , "A Phase 1 Study, in Cystic Fibrosis Patients, of the Safety, Toxicity, and Biological Efficacy of a Single Administration of a Replication Deficient, Recombinant Adenovirus Carrying the cDNA of the Normal Cystic Fibrosis Transmembrane Conductance Regulator Gene in the Lung," (1995) <u>Hum. Gene Therapy</u> 6:643-666		
	C46	Crystal, R.G. <i>et al.</i> , "Evaluation of Repeat Administration of a Replication Deficient, Recombinant Adenovirus Containing the Normal Cystic Fibrosis Transmembrane Conductance Regulator cDNA to the Airways of Individuals with Cystic Fibrosis," (1995) <u>Hum. Gene Therapy</u> 6:667-703		
	C47	Crystal, R.G., "Transfer of Genes to Humans: Early Lessons and Obstacles to Success," (1995) <u>Science</u> 270:404-410		
	C48	Csete, M.E. <i>et al.</i> , "Efficient Gene Transfer to Pancreatic Islets Mediated by Adenoviral Vectors," (1995) <u>Transplantation</u> 27:263-268		
	C49	Cunningham, B.C. and J.A. Wells, "Rational design of receptor-specific variants of human growth hormone," (1991) <u>Proc. Natl. Acad. Sci. USA</u> 88:3407-3411		
	C50	de la Fuente, M.A. <i>et al.</i> , "CD84 Leukocyte Antigen Is a New Member of the Ig Superfamily," (1997) <u>Blood</u> 90:2398-2405		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/525,743
				Filing Date	09/26/2005
				First Named Inventor	Vicki S. Elliott
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	7	of	18	Attorney Docket Number	059314-0701 (previously 039386-2252)

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	C51	deVries <i>et al.</i> , "Differential Display Identification of 40 Genes with Altered Expression in Activated Human Smooth Muscle Cells," (2000) <u>J. Biol. Chem.</u> 275:23939-23947		
	C52	Dryga, S.A. <i>et al.</i> , "Identification of Mutations in a Sindbis Virus Variant Able to Establish Persistent Infection in BHK Cells: The Importance of a Mutation in the nsP2 Gene," (1997) <u>Virology</u> 228:74-83		
	C53	Dull, T. <i>et al.</i> , "A Third-Generation Lentivirus Vector with a Conditional Packaging System," (1998) <u>J. Virol.</u> 72:8463-8471		
	C54	Duplaa, C. <i>et al.</i> , "Quantitative analysis of polymerase chain reaction products using biotinylated dUTP incorporation," (1993) <u>Anal. Biochem.</u> 212:229-236		
	C55	Eddy, S.R., "Hidden Markov Models," (1996) <u>Curr. Opin. Struct. Biol.</u> 6:361-365		
	C56	Elbashir, S.M. <i>et al.</i> , "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," (2001) <u>Nature</u> 411:494-498		
	C57	Engelhard, E.K. <i>et al.</i> , "The insect tracheal system: a conduit for the systemic spread of Autographa californica M nuclear polyhedrosis virus," (1994) <u>Proc. Natl. Acad. Sci. USA</u> 91:3224-3227		
	C58	Fields, S. and O. Song, "A Novel Genetic System to Detect Protein-Protein Interactions," (1989) <u>Nature</u> 340:245-246		
	C59	Fire, A. <i>et al.</i> , "Potent and specific genetic interference by double-stranded RNA in <i>Caenorhabditis elegans</i> ," (1998) <u>Nature</u> 391:806-811		
	C60	Garoff, H. and K.-J. Li, "Recent advances in gene expression using alphavirus vectors," (1998) <u>Curr. Opin. Biotechnol.</u> 9:464-469		
	C61	Gatti, R.A. <i>et al.</i> , "Localization of an Ataxia-Telangiectasia Gene to Chromosome," (1988) <u>Nature</u> 336:577-580		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	10/525,743
		<b>Filing Date</b>	09/26/2005
		<b>First Named Inventor</b>	Vicki S. Elliott
		<b>Group Art Unit</b>	Unassigned
		<b>Examiner Name</b>	Unassigned
(use as many sheets as necessary)		<b>Attorney Docket Number</b>	059314-0701 (previously 039386-2252)
Sheet	8	of	18

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C62	Gebe, J.A., "Molecular Cloning, Mapping to Human Chromosome 1q21-q23, and Cell binding Characteristics of Spd, a New Member of the Scavenger Receptor Cysteine-rich (SRCR) Family of Proteins," (1997) <u>J. Biol. Chem.</u> 272:6151-6158	
	C63	Goins, W.F. <i>et al.</i> , "Herpes Simplex Virus Type 1 Vector-Mediated Expression of Nerve Growth Factor Protects Dorsal Root Ganglion Neurons from Peroxide Toxicity," (1999) <u>J. Virol.</u> 73:519-532	
	C64	Goldman, C.K. <i>et al.</i> , "In Vitro and In Vivo Gene Delivery Mediated by a Synthetic Polycationic Amino Polymer," (1997) <u>Nat. Biotechnol.</u> 15:462-466	
	C65	Gossen, M. and H. Bujard, "Tight control of gene expression in mammalian cells by tetracycline-responsive promoters," (1992) <u>Proc. Natl. Acad. Sci. USA</u> 89:5547-5551	
	C66	Gossen, M. <i>et al.</i> , "Transcriptional Activation by Tetracyclines in Mammalian Cells," (1995) <u>Science</u> 268:1766-1769	
	C67	Graham, F.L. and A.J. Eb, "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA," (1973) <u>Virology</u> 52:456-467	
	C68	Gregoire, F.M. <i>et al.</i> , "Understanding Adipocyte Differentiation," (1998) <u>Physiol. Reviews</u> 78:783-809	
	C69	Gura, T., "A silence that speaks volumes," (2000) <u>Nature</u> 404:804-808	
	C70	Haft, D.H. <i>et al.</i> , "TIGRFAMs: a protein family resource for the functional identification of proteins," (2001) <u>Nucleic Acids Res.</u> 29:41-43	
	C71	Haley <i>et al.</i> , "Overexpression of Eotaxin and the CCR3 Receptor in Human Atherosclerosis : Using Genomic Technology to Identify a Potential Novel Pathway of Vascular Inflammation," (2000) <u>Circulation</u> 102:2185-2189	
	C72	Harrington, M.G., "Elution of Protein From Gels," (1990) <u>Methods Enzymol.</u> 182:488-495	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Complete if Known</b>	
		Application Number	10/525,743
		Filing Date	09/26/2005
		First Named Inventor	Vicki S. Elliott
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
(use as many sheets as necessary)		Attorney Docket Number	059314-0701 (previously 039386-2252)
Sheet	9	of	18

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C73	Harrington, J.J. <i>et al.</i> , "Formation of <i>De Novo</i> Centromere and Construction of First-Generation Human Artificial Microchromosomes," (1997) <u>Nat. Genet.</u> 15:345-355	
	C74	Hartman, S.C. and R.C. Mulligan, "Two dominant-acting selectable markers for gene transfer studies in mammalian cells," (1988) <u>Proc. Natl. Acad. Sci. USA</u> 85:8047-8051	
	C75	Heller, R.A. <i>et al.</i> , "Discovery and analysis of inflammatory disease-related genes using cDNA microarrays," (1997) <u>Proc. Natl. Acad. Sci. USA</u> 94:2150-2155	
	C76	Higgins, D.G. <i>et al.</i> , "CLUSTAL V: Improved Software for Multiple Sequence Alignment," (1992) <u>CABIOS</u> 8:189-191	
	C77	Higgins, D.G. and P.M. Sharp, "Fast and Sensitive Multiple Sequence Alignments on a Microcomputer," (1989) <u>CABIOS</u> 5:151-153	
	C78	Hiraga, S. <i>et al.</i> , "Modulation of Collagen Synthesis by Tumor Necrosis Factor Alpha in Cultured Vascular Smooth Muscle Cells," (2000) <u>Life Sci.</u> 66:235-244	
	C79	Holden, R.J. <i>et al.</i> , "Tumor Necrosis Factor- $\alpha$ : A Continuum of Liability Between Insulin-Dependent Diabetes Mellitus, Non-Insulin-Dependent Diabetes Mellitus And C Arcinoma (review) (1999) <u>Med. Hypotheses</u> 52:319-23	
	C80	Horn, T. <i>et al.</i> , "Synthesis of oligonucleotides on cellulose. Part II: design and synthetic strategy to the synthesis of 22 oligodeoxynucleotides coding for Gastric Inhibitory Polypeptide (GIP)," (1980) <u>Nucleic Acids Symp. Ser.</u> 7:225-232	
	C81	Horrevoets <i>et al.</i> , "Vascular Endothelial Genes That Are Responsive to Tumor Necrosis Factor- $\alpha$ In Vitro Are Expressed in Atherosclerotic Lesions, Including Inhibitor of Apoptosis Protein-1, Stannin, and Two Novel Genes," (1999) <u>Blood</u> 93:3418-3431	
	C82	Howard, A.D. <i>et al.</i> , "Orphan G-Protein-Coupled Receptors and Natural Ligand Discovery," (2001) <u>Trends Pharmacol. Sci.</u> 22:132-140	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Application Number</b>	10/525,743
				<b>Filing Date</b>	09/26/2005
				<b>First Named Inventor</b>	Vicki S. Elliott
				<b>Group Art Unit</b>	Unassigned
				<b>Examiner Name</b>	Unassigned
(use as many sheets as necessary)				<b>Attorney Docket Number</b>	059314-0701 (previously 039386-2252)
Sheet	10	of	18		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>	
	C83	Huse, W.D. <i>et al.</i> , "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," (1989) <u>Science</u> 246:1275-1281		
	C84	Ivics, Z., "Molecular Reconstruction of <i>Sleeping Beauty</i> , a <i>Tc1</i> -like Transposon from Fish, and Its Transposition in Human Cells," (1997) <u>Cell</u> 91:501-510		
	C85	Khazaie, K. <i>et al.</i> , "EGF Receptor in Neoplasia and Metastasis," (1993) <u>Cancer and Metastasis Rev.</u> 12:255-274		
	C86	Kimmel, A.R., "Identification and Characterization of Specific Clones: Strategy for Confirming the Validity of Presumptive Clones," (1987) <u>Methods Enzymol.</u> 152:507-511		
	C87	Kohler, G. <i>et al.</i> , "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," (1975) <u>Nature</u> 256:495-497		
	C88	Kozbor, D. <i>et al.</i> , "Specific Immunoglobulin Production and Enhanced Tumorigenicity Following Ascites Growth of Human Hybridomas," (1985) <u>J. Immunol. Methods</u> 81:31-42		
	C89	Kwok, P.-Y. and Z. Gu, "Single Nucleotide Polymorphism Libraries: Why and How Are We Building Them?" (1999) <u>Mol. Med. Today</u> 5:538-543		
	C90	Lagerstrom, M. <i>et al.</i> , "Capture PCR: efficient amplification of DNA fragments adjacent to a known sequence in human and YAC DNA," (1991) <u>PCR Methods Applic.</u> 1:111-119		
	C91	Lander, E.S. and D. Botstein, "Strategies for studying heterogeneous genetic traits in humans by using a linkage map of restriction fragment length polymorphisms," (1986) <u>Proc. Natl. Acad. Sci. USA</u> 83:7353-7357		
	C92	Lee, S.W. <i>et al.</i> (1992), "Down-regulation of a member of the S100 gene family in mammary carcinoma cells and reexpression by azadeoxycytidine treatment," <u>Proc. Natl. Acad. Sci. USA</u> 89:2504-2508		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	10/525,743
		<b>Filing Date</b>	09/26/2005
		<b>First Named Inventor</b>	Vicki S. Elliott
		<b>Group Art Unit</b>	Unassigned
		<b>Examiner Name</b>	Unassigned
(use as many sheets as necessary)		<b>Attorney Docket Number</b>	059314-0701 (previously 039386-2252)
Sheet	11	of	18

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C93	Letunic, I. <i>et al.</i> , "Recent improvements to the SMART domain-based sequence annotation resource," (2002) <u>Nucleic Acids Res.</u> 30:242-244	
	C94	Liu, X. <i>et al.</i> , Herpes Simplex Virus Mediated Gene Transfer to Primate Ocular Tissues," (1999) <u>Exp. Eye Res.</u> 169:385-395	
	C95	Logan, J. and T. Shenk, "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection," (1984) <u>Proc. Natl. Acad. Sci. USA</u> 81:3655-3659	
	C96	Lois, C. <i>et al.</i> , "Germline Transmission and Tissue-Specific Expression of Transgenes Delivered by Lentiviral Vectors," (2002) <u>Science</u> 295:868-872	
	C97	Lowman, H.B. <i>et al.</i> , "Mutational Analysis and Protein Engineering of Receptor-Binding Determinants in Human Placental Lactogen," (1991) <u>J. Biol. Chem.</u> 266:10982-10988	
	C98	Lowy, I. <i>et al.</i> , "Isolation of Transforming DNA: Cloning the Hamster apt Gene," (1980) <u>Cell</u> 22:817-823	
	C99	Lueking, A. <i>et al.</i> , "Protein Microarrays for Gene Expression and Antibody Screening," (1999) <u>Anal. Biochem.</u> 270:103-111	
	C100	Manda <i>et al.</i> , "Identification of Genes (SPON2 and C20orf2) Differentially Expressed Between Cancerous and Noncancerous Lung Cells by mRNA Differential Display," (1999) <u>Genomics</u> 51:5-14	
	C101	Mantovani, A. <i>et al.</i> , "Decoy Receptors: A Strategy to Regulate Inflammatory Cytokines and Chemokines," (2001) <u>Trends Immunol.</u> 22:328-336	
	C102	Marshall, A. and J. Hodgson, "DNA Chips: an Array of Possibilities," (1998) <u>Nat. Biotechnol.</u> 16:27-31	
	C103	Marth, J.D., "Recent advances in gene mutagenesis by site-directed recombination," (1996) <u>Clin. Invest.</u> 97:1999-2002	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/525,743
				Filing Date	09/26/2005
				First Named Inventor	Vicki S. Elliott
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	12	of	18	Attorney Docket Number	059314-0701 (previously 039386-2252)

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>	
	C104	Matthews, D.J. and J.A. Wells, "Engineering an Interfacial Zinc Site to Increase Hormone-Receptor Affinity," (1994) <u>Chem. Biol.</u> 1:25-30		
	C105	McGregor, D.P. <i>et al.</i> , "Spontaneous Assembly of Bivalent Single Chain Antibody Fragments in <i>ESCHERICHIA COLI</i> ," (1994) <u>Mol. Immunol.</u> 31:219-226		
	C106	Melby, P.C. <i>et al.</i> , "Quantitative Measurement of Human Cytokine Gene Expression by Polymerase Chain Reaction," (1993) <u>J. Immunol. Methods</u> 159:235-244		
	C107	Mendoza, L.G. <i>et al.</i> , "High-throughput microarray-based enzyme-linked immunosorbent assay (ELISA)," (1999) <u>Biotechniques</u> 27:778-788		
	C108	Miller, A.D., "Progress Toward Human Gene Therapy," (1990) <u>Blood</u> 76:271-278		
	C109	Morgan, R.A. and W.F. Anderson, "Human Gene Therapy," (1993) <u>Annu. Rev. Biochem.</u> 62:191-217		
	C110	Morris, M.C. <i>et al.</i> , "A new peptide vector for efficient delivery of oligonucleotides into mammalian cells," (1997) <u>Nucleic Acids Res.</u> 25:2730-2736		
	C111	Morrison, S.L. <i>et al.</i> , "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," (1984) <u>Proc. Natl. Acad. Sci. USA</u> 81:6851-6855		
	C112	Muyldermans, S., "Single domain camel antibodies: current status, " (2001) <u>J. Biotechnol.</u> 74:277-302		
	C113	Neuberger, M.S. <i>et al.</i> , "Recombinant Antibodies Possessing Novel Effector Functions," (1984) <u>Nature</u> 312:604-608		
	C114	Neumann, E. <i>et al.</i> , "Gene Transfer Into Mouse Lyoma Cells by Electroporation in High Electric Fields," (1982) <u>EMBO J.</u> 1:841-845		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/525,743
				Filing Date	09/26/2005
				First Named Inventor	Vicki S. Elliott
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	13	of	18	Attorney Docket Number	059314-0701 (previously 039386-2252)

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>	
	C115	Nowotny, P. <i>et al.</i> , "SNP analysis to dissect human traits," (2001) <u>Curr. Opin. Neurobiol.</u> 11:637-641		
	C116	Nuwaysir, E.F. <i>et al.</i> , "Microarrays and Toxicology: The Advent of Toxicogenomics," (1999) <u>Mol. Carcinog.</u> 24:153-159		
	C117	Ohta, M.Y. <i>et al.</i> , "Inhibitory Effect of Troglitazone on TNF- $\alpha$ Induced Expression of Monocyte Chemoattractant Protein-1 (MCP-1) in Human Endothelial Cells," (2000) <u>Diabetes Res. Clin. Pract.</u> 48:171-176		
	C118	Orlandi, R. <i>et al.</i> , Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," (1989) <u>Proc. Natl. Acad. Sci. USA</u> 86:3833-3837		
	C119	Paddison, P.J. <i>et al.</i> , "Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells," (2002) <u>Genes Dev.</u> 16:948-958		
	C120	Parker, J.D. <i>et al.</i> , "Targeted gene walking polymerase chain reaction," (1991) <u>Nucleic Acids Res.</u> 19:3055-3060		
	C121	Perou, C.M. <i>et al.</i> , "Molecular portraits of human breast tumours," (2000) <u>Nature</u> 406:747-752		
	C122	Petersen <i>et al.</i> , "Gene Therapy Expression Profiling of Advanced Lung Cancer," (2000) <u>Int J. Cancer</u> , 86:512-517		
	C123	Poeschla, E. <i>et al.</i> , "Development of HIV Vectors for Anti-HIV Gene Therapy," (1996) <u>Proc. Natl. Acad. Sci. USA</u> 93:11395-11399		
	C124	Ranga, U. <i>et al.</i> , "Cell and viral regulatory elements enhance the expression and function of a human immunodeficiency virus inhibitory gene," (1997) <u>J. Virol.</u> 71:7020-7029		
	C125	Ranga, U. <i>et al.</i> , "Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals," (1998) <u>Proc. Natl. Acad. Sci. USA</u> 95:1201-1206		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Application Number</b>	10/525,743
				<b>Filing Date</b>	09/26/2005
				<b>First Named Inventor</b>	Vicki S. Elliott
				<b>Group Art Unit</b>	Unassigned
				<b>Examiner Name</b>	Unassigned
(use as many sheets as necessary)				<b>Attorney Docket Number</b>	059314-0701 (previously 039386-2252)
Sheet	14	of	18		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>	
	C126	Rao, V.B., "Direct Sequencing of Polymerase Chain Reaction-Amplified DNA," (1994) <u>Anal. Biochem.</u> 216:1-14		
	C127	Rhodes, C.A., "Transformation of Maize by electroporation of Embryos," (1995) <u>Methods Mol. Biol.</u> 55:121-131		
	C128	Riviere, I. <i>et al.</i> , "Effects of Retroviral Vector Design on Expression of Human Adenosine Deaminase in Murine Bone Marrow Transplant Recipients Engrafted with Genetically Modified Cells," (1995) <u>Proc. Natl. Acad. Sci. USA</u> 92:6733-6737		
	C129	Roberge, J.Y. <i>et al.</i> , "A Strategy for a Convergent Synthesis of N-Linked Glycopeptides on a Solid Support," (1995) <u>Science</u> 269:202-204		
	C130	Rossi, F.M.V. and H.M. Blau, "Recent Advances in Inducible Gene Expression Systems," (1998) <u>Curr. Opin. Biotechnol.</u> 9:451-456		
	C131	Rossi, J.J., "Therapeutic antisense and ribozymes," (1995) <u>Br. Med. Bull.</u> 51:217-225		
	C132	Sager, R. <i>et al.</i> , "Maspin: A Tumor Suppressing Serpin," (1996) <u>Curr. Top. Microbiol. Immunol.</u> 213:51-64		
	C133	Sandig, V. <i>et al.</i> , "Gene Transfer into Hepatocytes and Human Liver Tissue by Baculovirus Vectors," (1996) <u>Hum. Gene Ther.</u> 7:1937-1945		
	C134	Sarkar, G., "Restriction-Site PCR: A Direct Method of Unknown Sequence Retrieval Adjacent to a Known Locus by Using Universal Primers," (1993) <u>PCR Methods Applic.</u> 2:318-322		
	C135	Scanlon, K.J. <i>et al.</i> , "Oligonucleotide-Mediated Modulation of Mammalian Gene Expression," (1995) <u>FASEB J.</u> 9:1288-1296		
	C136	Scharf, D. <i>et al.</i> , "Heat Stress Promoters and Transcription Factors," (1994) <u>Results Probl. Cell Differ.</u> 20:125-162		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/525,743
				Filing Date	09/26/2005
				First Named Inventor	Vicki S. Elliott
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	15	of	18	Attorney Docket Number	059314-0701 (previously 039386-2252)

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
	C137	Schena, M. <i>et al.</i> , "Parallel Human Genome Analysis: Microarray-Based Expression Monitoring of 1000 Genes," (1996) <u>Proc. Natl. Acad. Sci. USA</u> 93:10614-10619			
	C138	Schena, M. <i>et al.</i> , "Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray," (1995) <u>Science</u> 270:467-470			
	C139	Schultz, J. <i>et al.</i> , "SMART, a simple modular architecture research tool: Identification of signaling domains," (1998) <u>Proc. Natl. Acad. Sci. USA</u> 95:5857-5864			
	C140	Schwarze, S.R. <i>et al.</i> , "In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse," (1999) <u>Science</u> 285:1569-1572			
	C141	Scorer, C.A. <i>et al.</i> , "Rapid Selection Using G418 of High Copy Number Transformants of <i>Pichia Pastoris</i> for High-Level Foreign Gene Expression," (1994) <u>Bio/Technology</u> 12:181-184			
	C142	Sears, D.W. <i>et al.</i> , "Molecular Cloning and Expression of the Mouse High Affinity Fc Receptor for IgG," (1990) <u>J. Immunol.</u> 144:371-378			
	C143	Shalon, D. <i>et al.</i> , "A DNA Microarray System for Analyzing Complex DNA Samples Using Two-Color Fluorescent Probe Hybridization," (1996) <u>Genome Res.</u> 6:639-645			
	C144	Skerra, A., "'Anticalins': A New Class of Engineered Ligand-Binding Proteins With Antibody-Like Properties," (2001) <u>J. Biotechnol.</u> 74:257-275			
	C145	Slater, J.E. <i>et al.</i> , "Environmental and Occupational Disorders," (1998) <u>J. Allergy Clin. Immunol.</u> 102:469-475			
	C146	Smith, C.A. <i>et al.</i> , "The TNF Receptor Superfamily of Cellular and Viral Proteins: Activation, Costimulation, and Death," (1994) <u>Cell</u> 76:959-962			
	C147	Steiner, S. and N.L. Anderson, "Expression Profiling in Toxicology—Potentials and Limitations," (2000) <u>Toxicol. Lett.</u> 112-113:467-471			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/525,743
				Filing Date	09/26/2005
				First Named Inventor	Vicki S. Elliott
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	16	of	18	Attorney Docket Number	059314-0701 (previously 039386-2252)

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>	
	C148	Su, L., "Hematopoietic Stem Cell-Based Gene Therapy for Acquired Immunodeficiency Syndrome: Efficient Transduction and Expression of RevM10 in Myeloid Cells In Vivo and In Vitro," (1997) <u>Blood</u> 89:2283-2290		
	C149	Suzuki, A. <i>et al.</i> , "Alteration in Expression Profiles of a Series of Diabetes-Related Genes in <i>db/db</i> Mice Following Treatment With Thiazolidinediones," (2000) <u>Jpn. J. Pharmacol.</u> 84:113-123		
	C150	Takamatsu, N., "Expression of Bacterial Chloramphenicol Acetyltransferase Gene in Tobacco Plants Mediated by TRV-RNA," (1987) <u>EMBO J.</u> 6:307-311		
	C151	Takeda, S. <i>et al.</i> , "Construction of Chimaeric Processed Immunoglobulin Genes Containing Mouse Variable and Human Constant Region Sequences," (1985) <u>Nature</u> 314:452-454		
	C152	Taylor, J.G. <i>et al.</i> , "Deconstructing Type 2 Diabetes," (2001) <u>Trends Mol. Med.</u> 7:507-512		
	C153	Taylor, P.C. <i>et al.</i> , "Immunotherapy for Rheumatoid Arthritis," (2001) <u>Curr. Opin. Immunol.</u> 13:611-616		
	C154	Taylor, S.I., "Using Genetic Variation to Study Human Disease," (1999) <u>Cell</u> 97:9-12		
	C155	Thomson, J.A. <i>et al.</i> , Embryonic Stem Cell Lines Derived from Human Blastocysts," (1998) <u>Science</u> 282:1145-1147		
	C156	Trask, B.J., "Fluorescence <i>in situ</i> Hybridization," (1991) <u>Trends Genet.</u> 7:149-154		
	C157	Triglia, T. <i>et al.</i> , "A procedure for in vitro amplification of DNA segments that lie outside the boundaries of known sequences," (1988) <u>Nucleic Acids Res.</u> 16:8186		
	C158	Uckert, W. and W. Walther, "Retrovirus-Mediated Gene Transfer in Cancer Therapy," (1994) <u>Pharmacol. Ther.</u> 63:323-347		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Complete if Known</b>			
		<b>Application Number</b>	10/525,743		
(use as many sheets as necessary)		<b>Filing Date</b>	09/26/2005		
		<b>First Named Inventor</b>	Vicki S. Elliott		
		<b>Group Art Unit</b>	Unassigned		
		<b>Examiner Name</b>	Unassigned		
Sheet	17	of	18	<b>Attorney Docket Number</b>	059314-0701 (previously 039386-2252)

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	C159	Ulrix, W. <i>et al.</i> , "The Differentiation-Related Gene 1, <i>Drg1</i> , Is Markedly Upregulated by Androgens in LNCaP Prostatic Adenocarcinoma Cells," (1999) <u>FEBS Lett</u> 455:23-26	
	C160	Van Heeke, G. and S.M. Schuster, "Expression of Human Synthetase in <i>Escherichia coli</i> ," (1989) <u>J. Biol. Chem.</u> 264:5503-5509	
	C161	Verma, I.M. and N. Somia, "Gene therapy - promises, problems and prospects," (1997) <u>Nature</u> , 18:389:239-242	
	C162	Wagner, K.U. <i>et al.</i> , "Cre-mediated gene deletion in the mammary gland," (1997) <u>Nucleic Acids Res.</u> , 25:4323-4330	
	C163	Wahl, G.M. and S.L. Berger, "Molecular Hybridization of Immobilized Nucleic Acids: Theoretical Concepts and Practical Considerations," (1987) <u>Methods Enzymol.</u> 152:399-407	
	C164	Wang <i>et al.</i> , "Identification of Genes Differentially Over-Expressed in Lung Squamous Cell Carcinoma Using Combination of cDNA subtraction and microarray Analysis," (2000) <u>Oncogene</u> 19:1519-1528	
	C165	Way, J.M. <i>et al.</i> , "Comprehensive Messenger Ribonucleic Acid Profiling Reveals That Peroxisome Proliferator-Activated Receptor $\gamma$ Activation Has Coordinate Effects on Gene Expression in Multiple Insulin-sensitive Tissues," (2001) <u>Endocrinology</u> 142:1269-1277	
	C166	Weiss, G.A. and H.B. Lowman, "Anticalins Versus Antibodies: Made-To-Order Binding Proteins for Small Molecules," (2000) <u>Chem. Biol.</u> 7:R177-R184	
	C167	Wigler, M. <i>et al.</i> , "Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells," (1977) <u>Cell</u> 11:223-232	
	C168	Wigler, M. <i>et al.</i> , "Transformation of mammalian cells with an amplifiable dominant-acting gene," (1980) <u>Proc. Natl. Acad. Sci. USA</u> 77:3567-3570	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Application Number</b>	10/525,743
				<b>Filing Date</b>	09/26/2005
				<b>First Named Inventor</b>	Vicki S. Elliott
				<b>Group Art Unit</b>	Unassigned
				<b>Examiner Name</b>	Unassigned
(use as many sheets as necessary)				<b>Attorney Docket Number</b>	059314-0701 (previously 039386-2252)
Sheet	18	of	18		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	C169	Winter, G. <i>et al.</i> , "Man-Made Antibodies," (1991) <u>Nature</u> 349:293-299		
	C170	Winter, J. <i>et al.</i> , "The Expression of Heat Shock Protein and Cognate Genes During Plant Development," (1991) <u>Results Probl. Cell Differ.</u> 17:87-105		
	C171	Wise, A. <i>et al.</i> , "Target Validation of G-Protein Coupled Receptors," (2002) <u>Drug Discovery Today</u> 7:235-246		
	C172	Wistuba, I.I. <i>et al.</i> , "Comparison of Features of Human Breast Cancer Cell Lines and Their Corresponding Tumors," (1998) <u>Clin. Cancer Res.</u> 4:2931-2938		
	C173	Xu, H. <i>et al.</i> , "Viral Transduction of <i>trkA</i> Into Cultured Nodose and Spinal Motor Newrons Conveys NGF Responsiveness," (1994) <u>Dev. Biol.</u> 163:152-161		
	C174	Yu, M. <i>et al.</i> , "A Hairpin Ribozyme Inhibits Expression of Diverse Strains of Human Immunodeficiency Virus Type 1," (1993) <u>Proc. Natl. Acad. Sci. USA</u> 90:6340-6344		
	C175	Yu, X. and Weissman, S.M., "Characterization of the Promoter of Human Leukocyte-Specific Transcript 1," (2000) <u>J. Biol. Chem.</u> 275:34597-34608		
	C176	Zabner, J. <i>et al.</i> , "Adenovirus-Mediated Gene Transfer Transiently Corrects the Chloride Transport Defect in Masal Epithelia of Patients with Cystic Fibrosis," (1993) <u>Cell</u> 75:207-216		
	C177	Zhou, Z. <i>et al.</i> , "Up-Regulation of Human Secreted Frizzled Homolog in Apoptosis and its Down-Regulation in Breat Tumors," (1998) <u>Int. J. Cancer</u> 78:95-99		
	C178	Zufferey, R. <i>et al.</i> , "Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery," (1998) <u>J. Virol.</u> 72:9873-9880		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.